Volume 12, Number 5—May 2006
THEME ISSUE
Tuberculosis Special Section
Research
Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
Table 2
Studies comparing isoniazid treatment with no treatment in HIV-uninfected populations*
Author, country, dates | Population | Intervention/comparison; blinding | Enrolled (n) INH/control | Follow-up; loss to follow-up; overall or INH vs. control | TB cases: culture positive/total (%) |
Definition of INH resistance | Resistant cases/total tested (% culture positive tested) |
Risk for resistant TB/1,000 |
||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
INH | Controls | INH | Controls | INH | Controls | RR (95% CI) | ||||||
Ferebee, USA, 1957–NS (18) | Household contacts of TB patients | 12 mo INH, 4–7 mg/kg/day/placebo; double blind | 7,755/7,996 | <10 y; 5.2% vs. 4.9% during Rx | NS/86 | NS/215 | >50 colonies growth in 0.2 μg/mL INH | 2/10 NS | 2/31 NS | 2.22 | 1.73 | 1.28 (0.20–8.07) |
Katz, USA, 1958–1964 (19) | Mental hospital patients with inactive lesions | 2 y INH, 300 mg daily/no treatment; not blind | 118/107 | <4 y post-Rx; 30.6% overall† | NS/9 | NS/10 | Resistance to >0.25 γ INH | 1/1 NS | 2/5 NS | 76.27 | 37.38 | 2.04 (0.52–8.08) |
Horwitz, Greenland, 1956–1963 (20) | 76 villages | 2 × 13 wk INH, 400 mg twice weekly/0.1 mg INH; double blind | 4,174/3,907 | 6 y; NS | 123/238 (51.7) | 186/323 (57.6) | (a) > 1 colony at >0.32 μg/mL INH | (a) 2/46 | (a) 5/66 | (a) 2.48 | (a) 6.26 | (a) 0.40 (0.08–1.97) |
(b) Equal to control tube at >0.32 μg/mL INH | (b) 2/46 (37) | (b) 1/66 (36) | (b) 2.48 | (b) 1.25 | (b) 1.98 (0.18–21.31) | |||||||
Comstock, USA (Alaska), 1957–1964 (21) | Residents of 28 villages and 2 boarding schools | 12 mo INH, 300 mg§ daily/placebo; double blind | 3,047/3,017 | Med.: 69.3 mo (range 43–76 mo); 5.3% observed for <40 mo | NS/58 | NS/141 | NS | 4/20 NS | 1/50 NS | 3.81 | 0.93 | 4.07 (0.47–34.98) |
Ferebee, USA, 1960–1967 (9) | Persons with inactive lesions | 12 mo INH, 5 m g/kg/day/placebo; NS | 701/714 | 5 y; 2.2% by 1967 | NS/18 | NS/49 | >50 colonies growth in 0.2 μg/mL INH | 2/5 NS | 2/25 NS | 10.27 | 5.49 | 1.87 (0.31–11.19) |
Pamra, India, 1958–1968 (22) | X-ray screening attendees with inactive TB | 12 mo INH, 3–4 mg/kg/day/placebo; NS | 139/178 | <5 y post-Rx; 8.6% vs. 11.2% | 10/18 (55.6) | 57/76 (75) | Growth on 1 μg/mL INH | 3/9 (90) | 6/52 (91) | 43.17 | 49.27 | 0.88 (0.24–3.15) |
Hong Kong Chest Service, Hong Kong, 1981–1987 (27) | Men with silicosis | 24 wk INH, 300 mg daily/placebo;double blind | 167/159 | 2–5 y; 15.8% at 5 y | 19/25 (76) | 29/36 (80.6) | >20 colonies in >1 culture at >0.2 mg/L INH | 5/19 (100) | 4/28 (97) | 39.39 | 32.35 | 1.22 (0.34–4.32) |
*INH, isoniazid; TB, tuberculosis; RR, relative risk; CI, confidence interval; NS, not stated; med., median; Rx, treatment.
†(a), definition of resistance as >1 colony growth at >0.32 μg/mL INH.
‡(b), definition of resistance as growth equal to control tube at >0.32 μg/mL INH.
§Children were given 5 mg/kg/day INH.
References
- Di Perri G, Cruciani M, Danzi MC, Luzzati R, De CG, Malena M, Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet. 1989;2:1502–4.PubMed
- De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis. 1999;3:457–65.PubMed
- Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons (Cochrane Review). The Cochrane Library, Issue 3. Chichester (UK): John Wiley & Sons; 2004.
- World Health Organization Global Tuberculosis Programme, Joint United Nations Programme on HIV/AIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV [cited 2006 Mar 20]. Geneva: The Organization; 1998. WHO/TB/98.255. Available from http://www.who.int/docstore/gtb/publications/TB_HIV_polstmnt/index.html
- Ferebee S. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28–106.PubMed
- Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). The Cochrane Library, Issue 4. Chichester (UK): John Wiley & Sons; 2003.
- Sankey SS, Weissfeld LA, Fine MJ, Kapoor WN. An assessment of the use of the continuity correction for sparse data in meta-analysis. Comm Statist Simulation Comput. 1996;25:1031–56. DOI
- David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20:810–4.PubMed
- Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis. 1962;85:490–510.PubMed
- Katz J, Kunofsky S, Damijonaitis V, Lafleur A, Caron T. Effect of isoniazid upon the reactivation of inactive tuberculosis; final report. Am Rev Respir Dis. 1965;91:345–50.PubMed
- Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ. 1966;35:509–26.PubMed
- Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:935–43.PubMed
- Pamra SP, Mathur GP. Effects of chemoprophylaxis on minimal pulmonary tuberculosis lesions of doubtful activity. Bull World Health Organ. 1971;45:593–602.PubMed
- Grzybowski S, Ashley MJ, Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J. 1976;114:607–11.PubMed
- Krebs A. The IUAT trial on isoniazid preventive treatment in persons with fibrotic lung lesions. Bull Int Union Tuberc. 1976;51:193–201.PubMed
- Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis. 1986;133:431–6.PubMed
- Rieder HL, Chonde MT, Myking H, Urbaniczik R, Laszlo A, Kim SJ, The public health service national tuberculosis reference laboratory and the national laboratory network: minimum requirements, role and operation in a low-income country. Paris: International Union against Tuberculosis and Lung Disease; 1998.
- Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735–9.PubMed
- World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: The Organization; 2004. WHO/HTM/TB/2004.330. Available from http://www.who.int/hiv/pub/tb/tbhiv/en/index.html
1Current affiliation: Department of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
Page created: January 12, 2012
Page updated: January 12, 2012
Page reviewed: January 12, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.